Stimulation of the globus pallidus internus in the treatment of Parkinson's disease: Long-term results of a monocentric cohort. by Lachenmayer, Lenard et al.
Accepted Manuscript
Stimulation of the globus pallidus internus in the treatment of Parkinson's disease:
Long-term results of a monocentric cohort
M.L. Lachenmayer, C. Bettschen, C. Bernasconi, K. Petermann, I. Debove, J.
Muellner, J.P. Michelis, J.M. Burgunder, J.K. Krauss, M.F. Oertel, C. Pollo, A. Kaelin-
Lang, M. Schüpbach
PII: S1353-8020(19)30102-6
DOI: https://doi.org/10.1016/j.parkreldis.2019.03.009
Reference: PRD 3977
To appear in: Parkinsonism and Related Disorders
Received Date: 26 June 2018
Revised Date: 6 March 2019
Accepted Date: 14 March 2019
Please cite this article as: Lachenmayer ML, Bettschen C, Bernasconi C, Petermann K, Debove I,
Muellner J, Michelis JP, Burgunder JM, Krauss JK, Oertel MF, Pollo C, Kaelin-Lang A, Schüpbach M,
Stimulation of the globus pallidus internus in the treatment of Parkinson's disease: Long-term results
of a monocentric cohort, Parkinsonism and Related Disorders (2019), doi: https://doi.org/10.1016/
j.parkreldis.2019.03.009.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
3
4
7
8
7
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
1
1
.
1
1
.
2
0
1
9
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Stimulation of the globus pallidus internus in the treatment of Parkinson’s  
disease: long-term results of a monocentric cohort 
Lachenmayer ML1†, Bettschen C1, Bernasconi C1, Petermann K1, Debove I1, Muellner J1, Michelis JP1, Burgunder 
JM1, Krauss JK2, Oertel MF3,4, Pollo C4, Kaelin-Lang A1,5, and Schüpbach M1.  
1Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Switzerland 
2Department of Neurosurgery, Medical School Hannover (MHH), Hannover, Germany 
3Department of Neurosurgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland 
4Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Switzerland 
5Neurocentro della Svizzera Italiana, Ospedale Regionale di Lugano, Lugano, Switzerland 
 
Abstract word count:  216 
Total word count (without references):  2423 
 
Key words:  Deep brain stimulation, GPi, Parkinson`s disease, long-term, follow-up 
Running title:  long-term follow-up of pallidal stimulation in PD 
 
† Corresponding Author: 
M. Lenard Lachenmayer, M.D. 
Department of Neurology 
Inselspital 
Bern University Hospital 
Freiburgstrasse 10 
3010 Bern, Switzerland 
Phone: +41 31 632 21 11 
Fax: +41 31 632 03 21 
E-mail: lenard.lachenmayer@insel.ch 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
Abstract 
Background: Pallidal deep brain stimulation (DBS) has shown to be beneficial in 
patients with advanced levodopa-responsive Parkinson’s disease (PD) in several 
short-term studies. However, reported long-term outcomes of pallidal DBS for PD are 
limited and contradictory. 
 
Methods: Eighteen consecutive PD patients were treated with unilateral or bilateral 
stimulation of the internal part of the globus pallidus (GPi). Assessments were carried 
out before and six months after neurosurgery, and annually thereafter for up to 16 
years (mean follow-up time: 6 years). Primary outcomes included motor signs (Uni-
fied PD Rating Scale [UPDRS]-III), activities of daily living (ADL, UPDRS-II), and 
levodopa-induced motor complications (UPDRS-IV).  
 
Results: The results show that GPi stimulation improves levodopa responsive PD 
motor signs (UPDRS-III), levodopa-induced motor complications (UPDRS-IV), and 
ADL (UPDRS-II) in advanced PD. Among motor signs, tremor showed the best re-
sponse to pallidal stimulation. Levodopa-induced motor complications and tremor 
showed improvements for more than 10 years after neurosurgery.  
 
Conclusions: The overall findings in our cohort demonstrate that pallidal stimulation 
is effective in reducing parkinsonian motor signs (UPDRS-III), particularly in the ‘off’-
medication state. Although the beneficial effects on bradykinesia, rigidity and ADL 
may be limited to 5 to 6 years, the follow up results indicate that the improvements of 
levodopa-induced motor complications (UPDRS-IV) and tremor can be sustained for 
more than 10 years.  
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Introduction 
Deep brain stimulation (DBS) of the internal part of the globus pallidus (GPi) is bene-
ficial in patients with advanced levodopa-responsive Parkinson’s disease (PD) with 
significant improvement of tremor, bradykinesia, rigidity, gait, postural stability, levo-
dopa-induced motor fluctuations, and dyskinesia in the first year after surgery [1-8]. 
However, reported long-term outcomes (>24 months post-surgery) of pallidal DBS for 
PD are limited and contradictory. While some follow-up studies indicate that the initial 
response to stimulation might disappear in the aftermath [3, 7, 9-11], others report a 
sustained improvement for up to 3-4 [12-17] or 6 years [18] after surgery. Here, we 
report on long-term results (up to 16 years) in a cohort of 18 PD patients treated with 
pallidal DBS and prospectively followed at the University Hospital of Bern. 
 
Patients  
Our cohort is a consecutive series of 18 patients (11 male and 7 female; mean age at 
time of surgery 64.8 ± 7.4 years) with advanced PD (mean disease duration at time 
of surgery 16.2 ± 6.8 years) who received unilateral (n=4) or bilateral (n=14) elec-
trode implantations for DBS of the GPi at the University Hospital of Bern. The selec-
tion criteria for neurosurgery included: (i) advanced PD; (ii) good response to levodo-
pa; (iii) medication-refractory motor fluctuations and levodopa-induced dyskinesia 
despite best medical treatment; (iv) absence of neurosurgical contraindications. 
Eleven patients received electrode implantation in the late 1990s, when only GPi-
DBS was performed at the University Hospital Bern. STN-DBS was introduced later 
and then became the preferred target for patients with normal cognition and without 
levodopa-resistant axial motor signs. Detailed patient characteristics are shown in 
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table 1. All patients provided consent for follow-up evaluations. The mean follow-up 
time was 6 years (range 1 to 16 years). The variance of follow up time is due to dif-
ferent time points of implantation and loss of follow up. During the observation period 
(1997 to 2015) six patients were lost for follow up due to death, one patient due to a 
spontaneous cerebral haemorrhage, one patient because of a change of residence, 
two patients because of unknown reasons and one patient denied further follow up 
visits. 
 
Methods  
The surgical procedure was performed as previously reported [6]. All patients under-
went postoperative axial computed tomography (CT) to monitor complications and 
verify electrode position. Correct electrode position was documented by the neuro-
surgeon for all patients. Lead position was retrospectively checked for seven patients 
by co-registration of the postoperative CT with preoperative T2-weighted magnetic 
resonance imaging (MRI) and showed no active contact outside the GPi. However, 
for eleven patients who received electrode implantation in the late 1990s, no digital 
CT scans were available for determination of lead position. Postoperatively, stimula-
tion settings and antiparkinson medication were gradually adapted based on patient 
need and clinical response. 
All patients underwent standardized clinical evaluations before and six months after 
neurosurgery, and annually thereafter as part of their routine long-term care. These 
evaluations included application of the Unified Parkinson’s Disease Rating Scale 
(UPDRS) [19] during both ‘off’- and ‘on’-medication periods, the Schwab and England 
scale of activities of daily living [20], the Mini-Mental Status Examination (MMSE) [21] 
and the Hamilton Depression Scale (HAM-D21) [22]. All motor assessments were 
videotaped.  
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The assessments were performed after an overnight withdrawal of antiparkinsonian 
medication in a defined ‘off’-drug condition, and in the best ‘on’-drug condition after 
administration of levodopa. During each visit, information on the dosage of levodopa 
and other antiparkinsonian drugs as well as stimulation parameters were obtained. 
Furthermore, technical failures were ruled out by measurements of impedance and 
battery load.  
Video motor assessments were scored by an independent rater in a blinded condition 
with the UPDRS part III, with the exception of rigidity. Comparison of blinded versus 
unblinded UPDRS-III assessments showed good agreement with an average differ-
ence of 3 UPDRS points (Bland-Altman plot). Therefore, the unblinded assessments 
that included ratings for rigidity were used for further statistical analysis. The analysis 
was exploratory and included all evaluable patients. No missing values were imputed. 
The two-sided Wilcoxon signed-rank test was used for paired comparisons of base-
line and follow-up examinations. P-values <0.05 were considered significant and no 
correction for multiple testing was applied. Statistical analysis of treatment efficacy 
compared to baseline was conducted for the follow up assessments at ≤ 1.5 years, 
1.5-≤ 3.5 years, 3.5-≤ 5.5 years, ≥ 5.5 years and 10 years. Authorization to perform 
the analysis was granted by the institutional review board (local ethics committee).  
 
Results 
Motor signs 
UPDRS-III score in the ‘off-medication/on-stimulation’ condition was significantly im-
proved by 26% (p=0.001; n=17) 1.5 years after surgery and after 5.5 years by 22% 
(p=0.027; n=10) when compared to baseline before surgery (n=18) (Fig.1A). Howev-
er, after 10 years (n=4), UPDRS-III almost reached baseline score (Tab.2). Tremor 
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showed the best response to pallidal stimulation (Fig. 1B), and this improvement 
(55%) was significantly sustained for >5.5 years after surgery (p=0.039; n=8) and 
even present (44%) 10 years after surgery (n=4; only descriptive statistics presented) 
(Tab.2). Rigidity was significantly improved by 24% up to 5.5 years (p=0.043; n=10), 
while beneficial effects on bradykinesia disappeared within 3.5 to 5.5 years 
(Fig.1C+D; Tab.2). ‘Axial’ signs, defined as the sum of the motor subscores for 
speech, gait, posture and postural stability (items 18, 27, 28, 29 and 30 of the UP-
DRS-III) were significantly improved by 19% (p=0.002; n=17) up to 3.5 years after 
surgery (Fig.1E; Tab.2) and showed a trend towards improvement up to 5.5 years 
(p=0.075; n=10). In the ‘on-medication/on-stimulation’ condition, the UPDRS-III score 
showed no improvement compared to baseline, but significant worsening after 5.5 
years (p=0.035) (Tab.2). 
 
Motor complications 
Levodopa-induced motor complications assessed with the UPDRS-IV were signifi-
cantly improved by about 50% up to 5.5 years after surgery (p=0.005; n=10) and re-
mained improved by 41% even >5.5 years after surgery (p=0.007; n=8). Ten years 
after surgery the UPDRS-IV was still improved by 26% (p=NA; n=4) (Fig.1G; Tab.2). 
Dyskinesia (UPDRS-IV items 32-34) were significantly improved for >5.5 years after 
surgery by 49% (p=0.007) (Fig.1H) and remained improved 10 years after surgery 
(22%). This improvement applied both to duration (item 32) and disability (item 33) 
(Tab.2). Motor fluctuations (UPDRS-IV items 36-39) were significantly improved for 
>5.5 years after surgery by 38% (p=0.035) (Fig.1I) and remained improved 10 years 
after surgery by 26% (p=NA; n=4) (Tab.2). 
 
Activities of daily living (ADL) 
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UPDRS-II was significantly improved by 28% (p<0.001; n=17) 1.5 years after sur-
gery, remained improved after 3.5 years by 21% (p=0.007; n=17), and showed a 
trend towards improvement (p=0.082; n=10) up to 5.5 years after surgery (Fig.1F, 
Tab.2). The Schwab and England scale consistently showed significant improvement 
of ADL up to 3.5 years after surgery (p=0.034) (Tab.2).  
 
Mood 
GPi-DBS significantly improved depression scores compared to pre-operative base-
line, with the average HAM-D21 score decreasing from 7.8 ± 5.0 (mean ± SD) to 4.5 
± 2.8.0 (p=0.002) up to 3.5 years (Tab.2). A linear regression model adjusted for the 
duration of follow-up identified a significant negative relationship between baseline 
score and change at the last visit (coefficient -0.91; p < 0.001 - Fig.1K). 
 
Levodopa equivalent daily dose (LEDD) 
Daily levodopa equivalent dose at the last postoperative follow up compared with 
baseline was stable on average (1102 ± 472 mg at baseline and 1161 ± 346 mg at 
last follow up, p=0.22), but had to be increased over time in some patients. 
 
Stimulation settings 
The average parameters were 2.1 ± 1.0 V amplitude, 176.3 ± 52.9 µs pulse width, 
and 128.6 ± 34.9 Hz frequency. Eighteen electrodes were stimulated in monopolar, 
ten in bipolar, and four in double monopolar mode. 
 
Case of longest follow up 
One patient with early onset PD (age 34 at onset), who received DBS implantation 20 
years after disease onset, showed a preserved levodopa-response over decades and 
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improvement of UPDRS-III (30%), UPDRS-IV (20%) and UPDRS-II (26%) 16 years 
after surgery (Fig.2A-C). Analysis of UPDRS-III subscores revealed a remarkable 
improvement of tremor and, to a lesser extent, bradykinesia, which was preserved 
over 16 years (Fig.2A-C; Video). One year after initial DBS implantation, electrodes 
were repositioned because of dislocation. 
 
Adverse effects 
There were no intraoperative complications. Device related complications occurred in 
seven of the patients during the observation time and required surgical intervention. 
Reasons for surgical interventions were once a dislocation with subsequent reposi-
tion of electrodes; three times a broken cable or lead; twice an infection of the wound, 
in one of these cases the battery and cables had to be removed and were later re-
placed; once a seroma, which led to a revision and change of the pulse generator. 
One patient suffered a spontaneous cerebral haemorrhage in the thalamus 33 
months after surgery with consecutive hemiparesis. Another patient developed tran-
sient psychosis 3 weeks after surgery. None of the patients suffered from permanent 
deficits related to the procedure.  
 
Discussion  
Our study confirms the effectiveness of GPi-DBS in improving levodopa-responsive 
PD motor signs, levodopa-induced motor complications, and ADL in advanced PD. 
These findings are consistent with other studies that suggest a robust improvement in 
motor signs and levodopa-induced dyskinesia after one year [1-6, 23-26].  
In addition, our long-term follow-up results show that motor benefit (UPDRS-III) is 
sustained in the ‘off-medication/on-stimulation’ up to 5.5 years after surgery, which is 
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in line with other reports that describe stable responses over time [12-18]. In particu-
lar, tremor was significantly improved in our patients >5.5 years after surgery and this 
benefit was retained even 10 years after surgery. However, statistical analysis was 
not applicable due the low number of patients (n=4). The beneficial effect for bradyki-
nesia disappeared after 3.5 years and for rigidity and axial motor signs after 5.5 
years. This decline might be related to the natural progression of PD as indicated by 
the worsening of UPDRS-III score in the ‘on-med/on-stim condition’ after 5.5 years 
compared to the baseline score in the ‘on-med condition’. Despite the worsening of 
the UPDRS-III score, the mean LEDD was stable, which can either be due to the ap-
pearance of levodopa resistant motor signs as it is common in advanced PD, or to 
suboptimal dosage of prescribed daily dopaminergic medications. As annual levodo-
pa challenge tests were performed with the aim to identify a dopaminergic reserve to 
optimize medical treatment in our patients, we think under-dosing with levodopa is a 
less likely explanation. Moreover, stable LEDD has also been reported by other long-
term GPi-DBS studies [7, 13]. 
Although MMSE scores decreased over time, no statistically significant cognitive 
worsening was noted (Tab.2). This might be explained by the small sample size, but 
also by the low sensitivity of the MMSE to detect early and mid-stage cognitive 
changes that occur in PD, as the MMSE assesses more amnestic and language-
based than executive functions [27]. Furthermore, no persistent DBS-related serious 
adverse effects were observed in the follow-up, providing further evidence for long-
term safety/tolerability of pallidal stimulation. Motor complications have been as-
sessed by history taking and quantified in the UPDRS-IV. However, as patient diaries 
were not used, we cannot estimate the number of hours per day spent with or without 
dyskinesia. Nevertheless, levodopa-induced motor complications assessed by the 
UPDRS-IV were significantly improved for more than 5.5 years. This improvement 
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accounted equally for levodopa induced dyskinesia and motor fluctuations and was 
maintained for 10 years, confirming the sustained efficacy of pallidal stimulation in the 
treatment of PD with levodopa-induced motor complications. In a single case with 
early onset PD and preserved levodopa-response over the years, clinically relevant 
improvement of motor signs, levodopa-induced motor complications, and ADL re-
mained even 16 years after surgery. The fact that this patient had a 20-year PD histo-
ry prior to implantation could indicate a very slow progression of the disease and 
therefore limits the generalizability of this example to the average PD case with pal-
lidal DBS.  
This study has several limitations. First, the statistical power was limited due to the 
small number of patients. This implies that statistically non-significant results are diffi-
cult to interpret. In addition, false positive findings cannot be excluded, so statistical 
tests can only have exploratory value. Second, 4 of the 18 patients had only unilat-
eral pallidal stimulation, but statistical analysis of patients with only bilateral pallidal 
stimulation revealed similar results, though less significant due to the smaller sample 
size. Moreover, in 11 patients the available imaging does not permit an exact locali-
zation of the therapeutic leads within the target. Therefore, variability of targeting may 
contribute to the differences in the outcome. Although subthalamic nucleus DBS be-
came available at our centre while the last 7 patients of this series were operated, the 
therapy decision remained unaffected by the availability of STN-DBS. Finally, the 
length of the follow-up period was variable due to the different time points of implan-
tation and loss of follow up. Therefore, no statistical analysis has been performed for 
the follow-up data after 10 years (n=4). 
 
In summary, pallidal DBS is effective in reducing parkinsonian motor signs, but bene-
ficial effects on bradykinesia and rigidity may be limited to 5 to 6 years. However, our 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
long-term results show for the first time that the remarkable improvements of levodo-
pa-induced motor complications and tremor were sustained for up to 10 years and in 
a single case for 16 years, confirming the long-term efficacy of GPi-DBS in advanced 
PD. Although ‘off’-drug phase motor improvement might be greater after STN-DBS 
[28, 29], our findings indicate that the GPi is a viable DBS target for treatment of PD 
motor signs and levodopa-induced motor complications with a sustained effect. 
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characteristics  
number of patients 18 
gender 11 male, 7 female 
Age at time of surgery 64.8 ± 7.4 
Age at onset illness 48.6 ± 8.5 
Duration of Parkinson's disease 16.2 ± 6.8 
UPDRS II              
OFF 
ON 
 
26.3 ± 8.5 
16.4 ± 4.8 
UPDRS III             
OFF 
ON 
 
50.6 ± 16.4 
25.3 ± 9.0 
UPDRS IV 13.4 ± 2.5 
Schwab&England  
OFF 
ON 
 
42.8 ± 16.4 
69.4 ± 17.3 
LEDD (mg) 1102 ± 472 
Table 1. Baseline characteristics of patients. Values are means ± SD. 
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Baseline   Year <=1.5  Year 1.5 - <=3.5  Year 3.5 - <=5.5  Year >5.5  Year 10 
item score n   score n 
delta 
(%) 
p-
value   score n 
delta 
(%) 
p-
value   score n 
delta 
(%) 
p-
value   score n 
delta 
(%) 
p-
value   score n 
delta 
(%) 
p-
value 
UPDRS-II OFF 5-17 26.3±8.5 18   18.8±5.6 17 -28 <0.001   20.6±5.2 17 -21 0.007   21.2±4.1 10 -19 0.0828   24.2±4.2 8 -8 0.1609   23.2±5.5 4 -12 NA 
UPDRS-III                 
OFF-MED ON-STIM 18-31 50.6±16.4 18   37.3±10.5 17 -26 0.0016   40.6±13.1 17 -20 0.0015   39.3±9.3 10 -22 0.0273   47.1±8.3 8 -7 0.207   52.2±9.3 4 3 NA 
           tremor 20, 21 6.3±4.7 18   3.6±3.4 17 -43 <0.001   3.7±3.4 17 -41 0.0021   2.8±3.3 10 -55 0.009   2.8±2.3 8 -55 0.0391   3.5±1.9 4 -44 NA 
           rigidity 22 8.9±4.4 18   7.2±2.9 17 -19 0.0059   7.7±3.3 17 -13 0.0779   6.7±2.5 10 -24 0.0436   8.5±4.1 8 -4 0.1829   10.5±1.0 4 15 NA 
           bradykinesia 19, 23-26, 31 22.8±6.7 18   17.3±4.5 17 -24 0.0069   18.7±6.6 17 -18 0.0077   20.6±5.9 10 -9 0.5519   23.6±3.8 8 3 0.999   26.8±5.3 4 15 NA 
           axial signs 18, 27-30 12.7±3.8 18   9.1±3.6 17 -28 0.0052   10.3±3.4 17 -19 0.0024   9.2±3.1 10 -27 0.0756   12.1±3.2 8 -5 0.3096   11.5±4.4 4 -9 NA 
UPDRS-III                      
ON-MED ON-STIM 18-31 25.3±9.0 18   20.5±7.3 17 -19 0.0797   22.6±8.2 17 -11 0.1181   26.7±7.0 10 5 0.999   35.3±7.9 8 28 0.0355   33.7±2.3 4 25 NA 
UPDRS-IV 32-42 13.4±2.5 18   6.6±2.5 17 -51 <0.001   6.6±2.7 17 -51 <0.001   6.5±3.5 10 -51 0.005   7.9±3.9 8 -41 0.0078   9.8±5.9 4 -26 NA 
     dyskinesia 32-34 4.9±2.3 18   1.8±1.4 17 -63 <0.001   2.0±1.6 17 -59 <0.001   1.9±1.7 10 -61 0.0057   2.5±2.0 8 -49 0.0078   3.8±3.2 4 -22 NA 
            duration 32 2.5±1.0 18   1.1±0.7 17 -56 <0.001   1.3±1.1 17 -48 0.0028   1.2±0.7 10 -52 0.0133   1.4±0.8 8 -44 0.0418   1.8±1.0 4 -28 NA 
            disability 33 2.9±0.9 18   0.7±0.8 17 -76 <0.001   0.9±0.9 17 -69 0.001   1.0±0.9 10 -66 0.0124   1.6±0.8 8 -45 0.022   2.0±0.8 4 -31 NA 
     fluctuations 36-39 4.7±0.8 18   3.1±1.3 17 -34 0.001   3.0±1.1 17 -36 0.0031   2.7±1.3 10 -43 0.0084   2.9±1.6 8 -38 0.0355   3.5±1.9 4 -26 NA 
Schwab&England OFF - 42.8±16.4 18   51.5±16.0 17 17 0.0024   49.7±12.1 17 14 0.0344   51.8±14.0 10 17 0.1248   45.9±12.7 8 8 0.2807   32.5±15 4 -24 NA 
HAM-D21 - 7.8±5.0 18   5.3±3.1 17 -32 0.0168   4.5±2.8 17 -26 0.0024   5.8±4.0 10 -25 0.0827   6.6±4.7 8 -15 0.2049   3.3±2.3 3 -57 NA 
MMSE - 26.6±3.1 18   26.7±3.0 17 0 0.9621   24.6±6.4 17 -8 0.6412   24.9±4.3 10 -6 0.677   24.1±3.5 8 -9 0.1829   22.8±7.6 3 -14 NA 
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Table 2. UPDRS-II-IV, Schwab and England, Hamilton-Depression-Scale (HAM-D21) and Mini-Mental Status Examination (MMSE) before and 
after neurosurgery. Values are means (± SD). n = number of patients. delta = mean percentage change in comparison to the baseline. 
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Figure 1. Boxplots of (A) UPDRS-III, (B-E) UPDRS-III subscores, (F) UPDRS-II in the off medication condition and (G) UPDRS-IV and (H, I)  
UPDRS-IV subscores. Scatter plot of (K) HAM-D21 score change versus baseline score; linear regression model: change ~ baseline ~ duration of 
observation period; multiple R-Squared: 0.62289, p=0.0007. 
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Highlights 
• Pallidal DBS is effective in reducing parkinsonian motor signs 
 
• Improvement of levodopa-induced motor complications and tremor by GPi-
DBS can be sustained for more than 10 years. 
 
• In a single case improvement of UPDRS-III (30%), UPDRS-IV (20%) and 
UPDRS-II (26%) was sustained for 16 years after GPi-DBS 
 
• Beneficial effects on bradykinesia and rigidity might disappear within 5 to 6 
years 
